Metabolic & Cardiometabolic
APOC3 loss-of-function variants decreases cardiovascular risk independent of LDL (via remnant/triglyceride lowering)
In plain terms: Do people born with a broken APOC3 gene get less heart disease?
Yes — independent human-genetics studies show APOC3 loss-of-function carriers have lifelong low triglycerides/remnants and markedly lower coronary risk, and one null variant is enriched in long-lived people.
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: Population patterns (Observational)
How the studies fall
What the evidence shows
<!-- vault-context --> Norwitz **affirms** this claim. Consensus below reflects independent literature only.
The evidence (7)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Dai 2019 · Lipids Health Dis | observational | supports | moderate | Review concluded APOC3 loss-of-function mutations lower triglycerides and reduce coronary artery disease risk. |
| Pollin 2008 · Science | observational | supports | moderate | Amish R19X null carriers: lower TG, higher HDL, lower LDL, less coronary calcification — apparent cardioprotection; small founder population. |
| Wulff/Nordestgaard/Tybjaerg-Hansen 2018 · Arterioscler Thromb Vasc Biol | observational | supports | high | Mediation+meta-analysis n=137,895: APOC3 LoF lowers IHD risk; effect mediated chiefly by remnant cholesterol/TG, NOT by LDL-C — supports LDL-independent pathway. |
| Saleheen 2017 · Nature | observational | supports | moderate | Human-knockout cohort: homozygous APOC3 LoF carriers showed blunted postprandial TG rise vs family controls; mechanistic confirmation of LoF effect on remnants. |
| Jorgensen 2014 · N Engl J Med | observational | supports | high | Copenhagen cohorts: APOC3 LoF (incl R19X) → 44% lower nonfasting TG and ~41% lower ischemic vascular disease risk; large independent replication. |
| Alam 2026 · Curr Cardiol Rep | mechanism | supports | moderate | Review of triglyceride-rich lipoprotein biology supports APOC3 inhibition as causally lowering cardiovascular risk via reduced remnant particles. |
| Crosby/NHLBI Exome Seq Project 2014 · N Engl J Med | observational | supports | high | Exome seq: APOC3 LoF carriers had 39% lower TG and ~40% lower CHD risk (OR 0.60); naturally randomized, independent of Norwitz network. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.